To require enforcement against misbranded egg alternatives.
Summary
What This Bill Does
Bars foods from using egg or egg-product market names unless they meet statutory criteria, directs FDA enforcement guidance and reporting, and nullifies inconsistent egg-labeling guidance.
Who Benefits and How
Consumers and traditional egg producers could benefit from labeling rules meant to more sharply distinguish eggs and egg products from alternatives sold under similar names.
Who Bears the Burden and How
Makers of egg alternatives could face stricter labeling and enforcement risk, and FDA would have to issue guidance, enforce the new standard, and report to Congress.
Key Provisions
- States findings about the nutritional value of eggs and the risk of consumer confusion from mislabeled alternatives.
- Prohibits foods from entering interstate commerce under an egg or egg-product market name unless they meet statutory criteria.
- Defines what qualifies as an egg, an egg product, and a market name for those products.
- Requires FDA draft and final guidance, nullifies inconsistent guidance, and requires a congressional enforcement report.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Bars foods from using egg or egg-product market names unless they meet statutory criteria, directs FDA enforcement guidance and reporting, and nullifies inconsistent egg-labeling guidance.
Key Policy Areas
Food Regulation, Agriculture, Consumer Protection
Primary Purpose
Bars foods from using egg or egg-product market names unless they meet statutory criteria, directs FDA enforcement guidance and reporting, and nullifies inconsistent egg-labeling guidance.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Consumers and traditional egg and egg-product producers seeking tighter labeling enforcement
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Manufacturers of egg alternatives and FDA officials carrying out the new enforcement regime
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMs. Stefanik (for herself and Mr. Deluzio) introduced the following …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Manufacturers of egg alternatives using egg-related market names
Consumers seeking clearer distinction between eggs and alternatives
FDA officials issuing guidance, enforcing the standard, and reporting to Congress
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary"
- → Secretary of Health and Human Services
- "commissioner"
- → Commissioner of Food and Drugs
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology